This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Radius' (RDUS) Q1 Earnings Miss Estimates, Sales Surpass
by Zacks Equity Research
Radius (RDUS) reports wider-than-expected loss but beats sales estimates in the first quarter. The company lowers guidance for 2020.
Endo (ENDP) Q1 Earnings Beat on Coronavirus-Led Stockpiling
by Zacks Equity Research
Endo's (ENDP) earnings and sales beat estimates in the first quarter owing to increased customer inventory purchasing due to the COVID-19 pandemic
Will Infinity Pharmaceuticals (INFI) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Infinity (INFI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Infinity (INFI) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Infinity (INFI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Infinity (INFI) Down 28.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Infinity (INFI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Infinity's IPI-549 Gets Fast Track Tag for Urothelial Cancer
by Zacks Equity Research
The FDA bestows a Fast Track designation on Infinity's (INFI) IPI-549 in combination with Opdivo for treating advanced urothelial cancer. Stock rise.
Company News for Mar 26, 2020
by Zacks Equity Research
Companies in the news are: CATS, INFI, PAYX, NBY
Infinity (INFI) Q4 Loss Wider Than Expected, IPI-549 in Focus
by Zacks Equity Research
Infinity (INFI) posts a wider-than-expected loss for the fourth quarter of 2019.
Infinity Pharmaceuticals (INFI) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Infinity (INFI) delivered earnings and revenue surprises of -5.26% and 8.83%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Verastem In-Licenses KRAS-Focused Drug From Chugai, Stock Up
by Zacks Equity Research
Verastem (VSTM) enters into an agreement with Chugai Pharmaceutical to gain worldwide rights to the latter's RAF/MEK inhibitor, CH5126766, for $3 million in upfront payment.
Infinity (INFI) Q3 Loss Wider Than Expected, IPI-549 in Focus
by Zacks Equity Research
Infinity's (INFI) wider-than-estimated loss in Q3 displeases investors. Revenues too fall short of the mark.
Infinity Pharmaceuticals (INFI) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Infinity (INFI) delivered earnings and revenue surprises of -11.11% and -59.65%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Verastem's (VSTM) Copiktra Gets Orphan Drug Designation
by Zacks Equity Research
Verastem's (VSTM) Copiktra gets orphan drug designation from the FDA for use in the treatment of T-Cell lymphoma.
Infinity's (INFI) IPI-549 in Focus in a Crowded Cancer Space
by Zacks Equity Research
Infinity (INFI) is currently focusing on the development of its lead immuno-oncology candidate IPI-549, an orally administered treatment that selectively inhibits phosphoinositide-3 kinase (PI3K)-gamma.
Infinity Initiates 2 Studies for Lead Candidate IPI-549
by Zacks Equity Research
Infinity (INFI) initiates two studies for IPI-549 -- a first-in-class, oral immuno-oncology product candidate.
Infinity (INFI) Down 22.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Infinity (INFI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Infinity (INFI) Q2 Loss Wider Than Expected, Sales Miss
by Zacks Equity Research
Infinity (INFI) posts wider-than-expected loss in the second quarter of 2019 and misses sales estimates.
Infinity Pharmaceuticals (INFI) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Infinity (INFI) delivered earnings and revenue surprises of -20.00% and -90.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Verastem Up on Positive Data From Early-Stage Copiktra Study
by Zacks Equity Research
Verastem (VSTM) presents encouraging data from an early-stage study evaluating its recently approved drug, Copiktra, for treating peripheral T-cell lymphoma.
Infinity (INFI) Up 6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Infinity (INFI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Infinity (INFI) Earnings and Sales Miss Estimates in Q1
by Zacks Equity Research
Infinity (INFI) posts wider-than-expected loss in the first quarter of 2019. Sales miss estimates in the quarter.
Infinity Pharmaceuticals (INFI) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Infinity (INFI) delivered earnings and revenue surprises of -380.00% and -78.73%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Infinity (INFI) Down 10% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Infinity (INFI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Beat Q1 Earnings Woes With These Sector ETFs & Stocks
by Sweta Killa
The Q1 earnings picture looks bleak with projected growth turning negative for the first time since the second quarter of 2016.
Will Infinity Pharmaceuticals Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Infinity Pharmaceuticals.